Arcoma AB develops, produces, and provides radiology solutions worldwide. More Details
Adequate balance sheet with reasonable growth potential.
Share Price & News
How has Arcoma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARCOMA is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ARCOMA's weekly volatility (4%) has been stable over the past year.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: ARCOMA underperformed the Swedish Medical Equipment industry which returned 47.3% over the past year.
Return vs Market: ARCOMA underperformed the Swedish Market which returned 34.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Arcoma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StInsiders are probably glad they sold their shares in Arcoma AB (STO:ARCOMA) after 10% drop
6 months ago | Simply Wall StIs Arcoma (STO:ARCOMA) A Risky Investment?
7 months ago | Simply Wall StIs Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Is Arcoma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARCOMA (SEK18.1) is trading below our estimate of fair value (SEK33.84)
Significantly Below Fair Value: ARCOMA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ARCOMA is unprofitable, so we can't compare its PE Ratio to the Swedish Medical Equipment industry average.
PE vs Market: ARCOMA is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARCOMA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARCOMA is good value based on its PB Ratio (4.3x) compared to the SE Medical Equipment industry average (5.2x).
How is Arcoma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARCOMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: ARCOMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ARCOMA's is expected to become profitable in the next 3 years.
Revenue vs Market: ARCOMA's revenue (19.8% per year) is forecast to grow faster than the Swedish market (3.8% per year).
High Growth Revenue: ARCOMA's revenue (19.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARCOMA's Return on Equity is forecast to be high in 3 years time
How has Arcoma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARCOMA is currently unprofitable.
Growing Profit Margin: ARCOMA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARCOMA is unprofitable, but has reduced losses over the past 5 years at a rate of 60.2% per year.
Accelerating Growth: Unable to compare ARCOMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARCOMA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.9%).
Return on Equity
High ROE: ARCOMA has a negative Return on Equity (-3.67%), as it is currently unprofitable.
How is Arcoma's financial position?
Financial Position Analysis
Short Term Liabilities: ARCOMA's short term assets (SEK60.7M) exceed its short term liabilities (SEK36.4M).
Long Term Liabilities: ARCOMA's short term assets (SEK60.7M) exceed its long term liabilities (SEK6.4M).
Debt to Equity History and Analysis
Debt Level: ARCOMA's debt to equity ratio (33.3%) is considered satisfactory.
Reducing Debt: ARCOMA's debt to equity ratio has reduced from 43.5% to 33.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ARCOMA has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARCOMA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Arcoma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARCOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARCOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARCOMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARCOMA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARCOMA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Sanna Rydberg (52 yo)
Ms. Sanna Rydberg serves as Board Member at Observe Medical ASA since June 2021. She serves as Chief Executive Officer at Arcoma AB. She has experience from leading positions, as Chief Executive Officer of...
Experienced Board: ARCOMA's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Arcoma AB's company bio, employee growth, exchange listings and data sources
- Name: Arcoma AB
- Ticker: ARCOMA
- Exchange: OM
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr236.242m
- Shares outstanding: 13.05m
- Website: https://www.arcoma.se
Number of Employees
- Arcoma AB
- Annavägen 1
- Kronoberg County
- 352 46
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skelet...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/17 22:25|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.